热门资讯> 正文

Reviva Pharmaceuticals GAAP每股收益为-0.25美元

2024-05-14 22:50

Reviva Pharmaceuticals press release (NASDAQ:RVPH): Q1 GAAP EPS of -$0.25.
As of March 31, 2024, the Company’s cash totaled approximately $12.0 million compared to approximately $23.4 million as of December 31, 2023.

More on Reviva Pharmaceuticals

Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment
Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals
Historical earnings data for Reviva Pharmaceuticals
Financial information for Reviva Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。